Do not change, adjust, or discontinue any medications or prescribed treatments without your physician's guidance and approval
Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine , 384(11), 989-1002
Wilding, J.P.H., Batterham, R.L., Calanna, S., et al
Every serious complication reported in Retatrutide trials involved dehydration as a contributing factor
10 In SUSTAIN FORTE, treatment with semaglutide 2 mg versus 1 mg at week 40 showed superior reduction in HbA1c and additional body weight loss in patients with T2D and elevated glycaemic levels (HbA1c 8%10%) on background metformin with or without a sulphonylurea
Reta for Laboratory Procurement Reta may be reviewed by laboratories, research organisations and procurement buyers who require clear product information before ordering